Health Law & Business News

Remdesivir Is Better Than Standard Covid Care, Report Says: NIH

May 22, 2020, 10:10 PM

The antiviral remdesivir is superior to the standard of care for the treatment of Covid-19, NIH says, citing a report published today in The New England Journal of Medicine.

  • “Ultimately, the findings support remdesivir as the standard therapy for patients hospitalized with Covid-19 and requiring supplemental oxygen therapy, according to the authors”
  • The study began Feb. 21, 2020, and enrolled 1,063 participants in 10 countries in 58 days
  • NOTE: Gilead Sciences’s remdesivir has been shown to benefit coronavirus patients in a clinical trial

To contact the reporter on this story:
Kim Chipman in Chicago at kchipman@bloomberg.net

To contact the editors...

To read the full article log in. To learn more about a subscription click here.